Targeting the increased Fe3+ content in tumors, we propose a novel molecular platform integrated cancer iron chelation therapy for 1H-magnetic resonance imaging (MRI) detection of β-galactosidase (β-gal) activity. Following this idea, we have designed, synthesized, and characterized a series of β-d-galactosides conjugated with various chelators and demonstrated the feasibility of this concept for assessing β-gal activity in solution by 1H-MRI T1 and T 2 relaxation mapping.
|Number of pages||8|
|State||Published - Apr 1 2013|
- T and T relaxation times
- responsive Fe-based H-MRI agent
- β-galactosidase detection